Loading…

Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: A preliminary study

Highlights • Co-utilization of TLR5 agonist and nano- vaccine increase it immunogenicity. • Nano-Vac/FliC Increased cellular and Th1 immune responses. • Nano-Vac/FliC shows good immunogenicity in lower dose of immunization.

Saved in:
Bibliographic Details
Published in:Immunology letters 2017-07, Vol.187, p.19-26
Main Authors: Rostami, Hajar, Ebtekar, Masoumeh, Ardestani, Mehdi Shafiee, Yazdi, Mohammad Hossein, Mahdavi, Mehdi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Co-utilization of TLR5 agonist and nano- vaccine increase it immunogenicity. • Nano-Vac/FliC Increased cellular and Th1 immune responses. • Nano-Vac/FliC shows good immunogenicity in lower dose of immunization.
ISSN:0165-2478
1879-0542
DOI:10.1016/j.imlet.2017.05.002